Immunological and Clinical Effects of Thymostimulin in Patients with Locally Advanced Non-Small-Cell Lung Cancer Treated with Combined Chemoradiotherapy

R. V. Iaffaioli, F. Caponigro, G. Facchini, A. Tortoriello, G. Panelli, P. Muto, G. Ferrante

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

We investigated the effects of thymostimulin (TST) vs placebo administration in a randomised trial performed in patients with locally advanced non-small-cell lung cancer treated with a combined modality programme that included hyperfractionated split-course thoracic radiation therapy plus chemotherapy. Grade 3 to 4 neutropenia, severe anaemia, treatment delays due to myelosuppression, and overall infectious event rate were all less frequent in TST-treated patients, but none of these differences reached statistical significance. However, the fungine infection rate was significantly lower in the TST group, and natural killer (NK) cell activity was significantly increased in TST-treated patients. TST is believed to work mainly as a complex immunomodulator, which acts through stimulation of T cell maturation, T cell-mediated cytotoxicity, lymphokine production by T cells, regulation of lymphoid cell functions, modulation of NK cell activity and, possibly, restoration of depressed monocyte and dendritic cell function. Our study confirms that TST is capable of improving the tolerance to antitumour treatment, and thus improving the outcome of therapy.

Original languageEnglish
Pages (from-to)209-214
Number of pages6
JournalDrug Investigation
Volume7
Issue number4
DOIs
Publication statusPublished - 1994

Fingerprint

Chemoradiotherapy
Non-Small Cell Lung Carcinoma
T-Lymphocytes
Natural Killer Cells
Lymphokines
Immunologic Factors
Neutropenia
Dendritic Cells
thymostimulin
Anemia
Monocytes
Radiotherapy
Thorax
Therapeutics
Placebos
Lymphocytes
Drug Therapy
Infection

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Immunological and Clinical Effects of Thymostimulin in Patients with Locally Advanced Non-Small-Cell Lung Cancer Treated with Combined Chemoradiotherapy. / Iaffaioli, R. V.; Caponigro, F.; Facchini, G.; Tortoriello, A.; Panelli, G.; Muto, P.; Ferrante, G.

In: Drug Investigation, Vol. 7, No. 4, 1994, p. 209-214.

Research output: Contribution to journalArticle

@article{3fb7c6127cc846cfbfd0219bfee039de,
title = "Immunological and Clinical Effects of Thymostimulin in Patients with Locally Advanced Non-Small-Cell Lung Cancer Treated with Combined Chemoradiotherapy",
abstract = "We investigated the effects of thymostimulin (TST) vs placebo administration in a randomised trial performed in patients with locally advanced non-small-cell lung cancer treated with a combined modality programme that included hyperfractionated split-course thoracic radiation therapy plus chemotherapy. Grade 3 to 4 neutropenia, severe anaemia, treatment delays due to myelosuppression, and overall infectious event rate were all less frequent in TST-treated patients, but none of these differences reached statistical significance. However, the fungine infection rate was significantly lower in the TST group, and natural killer (NK) cell activity was significantly increased in TST-treated patients. TST is believed to work mainly as a complex immunomodulator, which acts through stimulation of T cell maturation, T cell-mediated cytotoxicity, lymphokine production by T cells, regulation of lymphoid cell functions, modulation of NK cell activity and, possibly, restoration of depressed monocyte and dendritic cell function. Our study confirms that TST is capable of improving the tolerance to antitumour treatment, and thus improving the outcome of therapy.",
author = "Iaffaioli, {R. V.} and F. Caponigro and G. Facchini and A. Tortoriello and G. Panelli and P. Muto and G. Ferrante",
year = "1994",
doi = "10.1007/BF03257412",
language = "English",
volume = "7",
pages = "209--214",
journal = "Clinical Drug Investigation",
issn = "1173-2563",
publisher = "Adis Press",
number = "4",

}

TY - JOUR

T1 - Immunological and Clinical Effects of Thymostimulin in Patients with Locally Advanced Non-Small-Cell Lung Cancer Treated with Combined Chemoradiotherapy

AU - Iaffaioli, R. V.

AU - Caponigro, F.

AU - Facchini, G.

AU - Tortoriello, A.

AU - Panelli, G.

AU - Muto, P.

AU - Ferrante, G.

PY - 1994

Y1 - 1994

N2 - We investigated the effects of thymostimulin (TST) vs placebo administration in a randomised trial performed in patients with locally advanced non-small-cell lung cancer treated with a combined modality programme that included hyperfractionated split-course thoracic radiation therapy plus chemotherapy. Grade 3 to 4 neutropenia, severe anaemia, treatment delays due to myelosuppression, and overall infectious event rate were all less frequent in TST-treated patients, but none of these differences reached statistical significance. However, the fungine infection rate was significantly lower in the TST group, and natural killer (NK) cell activity was significantly increased in TST-treated patients. TST is believed to work mainly as a complex immunomodulator, which acts through stimulation of T cell maturation, T cell-mediated cytotoxicity, lymphokine production by T cells, regulation of lymphoid cell functions, modulation of NK cell activity and, possibly, restoration of depressed monocyte and dendritic cell function. Our study confirms that TST is capable of improving the tolerance to antitumour treatment, and thus improving the outcome of therapy.

AB - We investigated the effects of thymostimulin (TST) vs placebo administration in a randomised trial performed in patients with locally advanced non-small-cell lung cancer treated with a combined modality programme that included hyperfractionated split-course thoracic radiation therapy plus chemotherapy. Grade 3 to 4 neutropenia, severe anaemia, treatment delays due to myelosuppression, and overall infectious event rate were all less frequent in TST-treated patients, but none of these differences reached statistical significance. However, the fungine infection rate was significantly lower in the TST group, and natural killer (NK) cell activity was significantly increased in TST-treated patients. TST is believed to work mainly as a complex immunomodulator, which acts through stimulation of T cell maturation, T cell-mediated cytotoxicity, lymphokine production by T cells, regulation of lymphoid cell functions, modulation of NK cell activity and, possibly, restoration of depressed monocyte and dendritic cell function. Our study confirms that TST is capable of improving the tolerance to antitumour treatment, and thus improving the outcome of therapy.

UR - http://www.scopus.com/inward/record.url?scp=0028226277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028226277&partnerID=8YFLogxK

U2 - 10.1007/BF03257412

DO - 10.1007/BF03257412

M3 - Article

VL - 7

SP - 209

EP - 214

JO - Clinical Drug Investigation

JF - Clinical Drug Investigation

SN - 1173-2563

IS - 4

ER -